Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 3/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CCR2 | P41597 | 4/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | CTSD | P07339 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9902990 | 0.84 | — | — | |
| SCHEMBL1249304 | 0.80 | CYP1A2 (0.37) | POLB | |
| SCHEMBL4592710 | 0.78 | CYP1A2 (0.33) | — | |
| SCHEMBL11294856 | 0.78 | CYP1A2 (0.32) | — | |
| SCHEMBL3694371 | 0.77 | CYP2C9 (0.40) | CYP2C9RAB9AEPHX1CCR2SMN1; SMN2 | |
| SCHEMBL10170261 | 0.74 | HPGD (0.53) | RAB9AHPGDNPC1EPHX1KMT2A | |
| SCHEMBL4251863 | 0.73 | APLNR (0.35) | — | |
| SCHEMBL658991 | 0.72 | HPGD (0.57) | RAB9AHPGDNPC1EPHX1KMT2A | |
| SCHEMBL1199614 | 0.71 | CYP1A2 (0.31) | — | |
| SCHEMBL23010991 | 0.70 | ANO1 (0.37) | RAB9AHPGDNPC1EPHX1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 499 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210212983-A1 | ORAL CANNABINOID DELIVERY FORMULATIONS WITH MOUTHFEEL EXPERIENCE ENHANCERS | CHICAGO ATLANTIC ADMIN, LLC | 2021-07-15 | — | — | US | claimed |
| EP-3169365-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OF ITCH | Westfälische Wilhelms-Universität Münster (DE) | 2017-05-24 | — | — | EP | claimed |
| EP-1924148-B1 | CONFECTIONERY COMPOSITION INCLUDING AN ELASTOMERIC COMPONENT, A COOKED SACCHARIDE COMPONENT, AND A SENSATE | INTERCONTINENTAL GREAT BRANDS LLC (US) | 2016-07-20 | — | — | EP | claimed |
| US-20160128944-A1 | COATED PARTICLES AND COMPOSITIONS COMPRISING SAME | VYOME THERAPEUTICS LIMITED (IN) | 2016-05-12 | — | — | US | claimed |
| US-9320705-B2 | Sensation modifying topical composition foam | FOAMIX PHARMACEUTICALS LTD. (IL) | 2016-04-26 | — | — | US | claimed |
| EP-3003031-A1 | COATED PARTICLES AND COMPOSITIONS COMPRISING SAME | Vyome Biosciences Pvt Ltd (IN) | 2016-04-13 | — | — | EP | claimed |
| WO-2015169884-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OF ITCH | WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER (DE) | 2015-11-12 | — | — | WO | claimed |
| WO-2014195872-A1 | COATED PARTICLES AND COMPOSITIONS COMPRISING SAME | VYOME BIOSCIENCES PVT. LTD. (IN) | 2014-12-11 | — | — | WO | claimed |
| US-20120237453-A1 | SENSATION MODIFYING TOPICAL COMPOSITION FOAM | FOAMIX LTD. (IL) | 2012-09-20 | — | — | US | claimed |
| EP-2355665-A1 | SENSATE- PLATED SANDING COMPOSITION AND PRODUCTS MADE THEREFROM | Kraft Foods Global Brands LLC (US) | 2011-08-17 | — | — | EP | claimed |
| US-20100129489-A1 | SENSATE-PLATED SANDING COMPOSITION AND PRODUCTS MADE THEREFROM | INTERCONTINENTAL GREAT BRANDS LLC | 2010-05-27 | — | — | US | claimed |
| WO-2010056697-A1 | SENSATE- PLATED SANDING COMPOSITION AND PRODUCTS MADE THEREFROM | CADBURY ADAMS USA LLC (US) | 2010-05-20 | — | — | WO | claimed |
| EP-2001448-A2 | FLAVOR-ENHANCING COMPOSITIONS, METHODS OF MANUFACTURE, AND METHODS OF USE | Cadbury Adams USA LLC (US) | 2008-12-17 | — | — | EP | claimed |
| EP-1973422-A1 | COMPOSITIONS PROVIDING A HEATING SENSATION FOR ORAL OR DERMAL DELIVERY | Cadbury Adams USA LLC (US) | 2008-10-01 | — | — | EP | claimed |
| WO-2007126430-A1 | COMPOSITIONS PROVIDING A HEATING SENSATION FOR ORAL OR DERMAL DELIVERY | CADBURY ADAMS USA LLC (US) | 2007-11-08 | — | — | WO | claimed |
| WO-2007089652-A2 | FLAVOR-ENHANCING COMPOSITIONS, METHODS OF MANUFACTURE, AND METHODS OF USE | CADBURY ADAMS USA LLC (US) | 2007-08-09 | — | — | WO | claimed |
| US-20070178123-A1 | FLAVOR-ENHANCING COMPOSITIONS, METHOD OF MANUFACTURE, AND METHODS OF USE | KRAFT FOODS GLOBAL BRANDS LLC | 2007-08-02 | — | — | US | claimed |
| US-20070148103-A1 | Compositions providing a heating sensation for oral or dermal delivery | CADBURY ADAMS USA, LLC. | 2007-06-28 | — | — | US | claimed |
| EP-3869971-B1 | CENTER-FILLED CONFECTIONERY PRODUCT; COATED PRODUCT; AND METHODS OF MAKING | INTERCONTINENTAL GREAT BRANDS LLC (US) | 2024-07-10 | — | — | EP | disclosed |
| US-20060263476-A1 | Center-filled chewing gum with barrier layer | CADBURY ADAMS USA, LLC. | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070148103-A1 | Compositions providing a heating sensation for oral or dermal delivery | TAS2R8, TAS2R60, TAS2R20 | CYP2C9 2003/4885RAB9A 2017/4885HPGD 1311/4885 |
| US-20120237453-A1 | SENSATION MODIFYING TOPICAL COMPOSITION FOAM | TRPA1, GPR35, TRPV1 | CYP2C9 2547/4885RAB9A 3788/4885HPGD 2513/4885 |
| US-20210212983-A1 | ORAL CANNABINOID DELIVERY FORMULATIONS WITH MOUTHFEEL EXPERIENCE ENHANCERS | CNR2, CNR1, CPNE4 | CYP2C9 332/4885RAB9A 1781/4885HPGD 782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.